6-(4′-Aryloxy-phenyl)vinyl-1,2,4-trioxanes: A new series of orally active peroxides effective against multidrug-resistant Plasmodium yoelii in Swiss mice

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 15, 2010, Pages 4459-4463

  Singh, Chandan ^a   Verma, Ved Prakash ^a   Naikade, Niraj Krishna ^a   Singh, Ajit Shankar ^a   Hassam, Mohammad ^a   Puri, Sunil K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

1,2,4 Trioxanes; Arteether; Malaria; Multidrug resistant

Indexed keywords

1,2,4 TRIOXANE DERIVATIVE; 3 [1 (4 PHENOXYPHENYL)VINYL] 1,2,5 TRIOXASPIRO[5.5]UNDECANE; 3 [1 [4 (BIPHENYL 4 YLOXY)PHENYL]VINYL] 1,2,5 TRIOXASPIRO[5.5]UNDECANE; 3 [1 [4 (NAPHTHALEN 1 YLOXY)PHENYL]VINYL] 1,2,5 TRIOXASPIRO[5.5]UNDECANE; 3 [1 [4 (NAPHTHALEN 2 YLOXY)PHENYL]VINYL] 1,2,5 TRIOXASPIRO[5.5]UNDECANE; 6 (4' ARYLOXYPHENYL)VINYL 1,2,4 TRIOXANE DERIVATIVE; 8 [1 (4 PHENOXYPHENYL)VINYL] 6,7,10 TRIOXASPIRO[4.5]DECANE; 8 [1 [4 (BIPHENYL 4 YLOXY)PHENYL]VINYL] 6,7,10 TRIOXASPIRO[4.5]DECANE; 8 [1 [4 (NAPHTHALEN 1 YLOXY)PHENYL]VINYL] 6,7,10 TRIOXASPIRO[4.5]DECANE; 8 [1 [4 (NAPHTHALEN 2 YLOXY)PHENYL]VINYL]6,7,10 TRIOXASPIRO[4.5]DECANE; ANTIMALARIAL AGENT; ARTEETHER; PEROXIDE; UNCLASSIFIED DRUG; 1,2,4 TRIOXANE; 1,2,4-TRIOXANE; HETEROCYCLIC COMPOUND; VINYL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARASITEMIA; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; TREATMENT DURATION; ANIMAL; CHEMISTRY; DRUG EFFECT; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

MUS; PLASMODIUM YOELII;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; DRUG RESISTANCE, MULTIPLE; HETEROCYCLIC COMPOUNDS; MICE; PLASMODIUM YOELII; STRUCTURE-ACTIVITY RELATIONSHIP; VINYL COMPOUNDS;

EID: 77955419972     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.045     Document Type: Article

References (45)

1. CDRI Communication No. 7544.
2. For reviews on artemisinin and its analogues see: D.L. Klayman Science 228 1985 1049
3. X.D. Luo, and C.C. Shen Med. Res. Rev. 7 1987 29
4. J.N. Cumming, P. Ploypradith, and G.H. Posner Adv. Pharmacol. 37 1997 253
5. A.K. Bhattacharya, and R.P. Sharma Heterocycles 51 1999 1681
6. K. Borstnik, I. Paik, T.A. Shapiro, and G.H. Posner Int. J. Parasitol. 32 2002 1661
7. P. Ploypradith Acta Trop. 89 2004 329
8. P.M. O'Neill, and G.H. Posner J. Med. Chem. 47 2004 2945
9. Y. Tang, Y. Dong, and J.L. Vennerstrom Med. Res. Rev. 24 2004 425
10. C.W. Jefford Curr. Opin. Investig. Drugs 5 2004 866
11. P.M. O'Neill, J. Chadwick, and S.L. Rawe Chemistry of Peroxides Vol. 2 2006 Wiley Chichester pp. 1279-1346
12. O.P. Asthana, J.S. Srivastava, and N. Valecha J. Parasitic Dis. 211 1997 1
13. WHO: Facts on ACTs (Artemisinin-based Combination Therapies), http://www.rbm.who.int/cmc.
14. G.H. Posner, I.-H. Paik, W. Chang, K. Borstnik, S. Sinishtaj, A.S. Rosenthal, and T.A. Shapiro J. Med. Chem. 50 2007 2516
15. J.A. Kepler, A. Philip, Y.W. Lee, C. Matthew, M.C. Morey, F. Ivy, and F.I. Carroll J. Med. Chem. 31 1988 713
16. W. Peters, B.L. Robinson, G. Tovey, J.C. Rossier, and C.W. Jefford Ann. Trop. Med. Parasitol. 87 1993 1
17. W. Peters, B.L. Robinson, J.C. Rossier, and C.W. Jefford Ann. Trop. Med. Parasitol. 87 1993 9
18. W. Peters, B.L. Robinson, G. Tovey, J.C. Rossier, and C.W. Jefford Ann. Trop. Med. Parasitol. 87 1993 111
19. G.H. Posner, J.P. Maxwell, H. O'Dowd, M. Krasavin, S. Xie, and T.A. Shapiro Bioorg. Med. Chem. 8 2000 1361
20. G.H. Posner, H.B. Jeon, M.H. Parker, M. Krasavin, I.-H. Paik, and T.A. Shapiro J. Med. Chem. 44 2001 3054
21. G.H. Posner, H.B. Jeon, P. Polypradith, I.-H. Paik, K. Borstnik, S. Xie, and T.A. Shapiro J. Med. Chem. 45 2002 3824
22. A.G. Griesbeck, T.T. El-Idreesy, M. Fiege, and R. Brun Org. Lett. 24 2002 4193
23. P.M. O'Neill, A. Mukhtar, S.A. Ward, J.F. Bickley, J. Davies, M.D. Bachi, and P.A. Stocks Org. Lett. 18 2004 3035
24. A.G. Griesbeck, T.T. EI-Idreesy, and J. Lex Tetrahedron 62 2006 10615
25. G.H. Posner, W. Chang, L. Hess, L. Woodard, S. Sinishtaj, A.R. Usera, W. Maio, A.S. Rosenthal, A.S. Kalinda, J.G.D. Angelo, K.S. Petersen, R. Stohler, J. Chollet, J. Santo-Tomas, C. Snyder, M. Rottmann, S. Wittlin, R. Burn, and T.A. Shapiro J. Med. Chem. 51 2008 1035
26. A.G. Griesbeck, J. Neudorfl, A. Horauf, S. Specht, and A. Raabe J. Med. Chem. 52 2009 3420
27. C. Singh Tetrahedron Lett. 31 1990 6901
28. C. Singh, D. Misra, G. Saxena, and S. Chandra Bioorg. Med. Chem. Lett. 2 1992 497
29. C. Singh, D. Misra, G. Saxena, and S. Chandra Bioorg. Med. Chem. Lett. 5 1995 1913
30. C. Singh, N. Gupta, and S.K. Puri Bioorg. Med. Chem. Lett. 13 2003 3447
31. C. Singh, H. Malik, and S.K. Puri Bioorg. Med. Chem. 12 2004 1177
32. C. Singh, N. Gupta, and S.K. Puri Bioorg. Med. Chem. 12 2004 5553
33. C. Singh, N.C. Srivastav, and S.K. Puri Bioorg. Med. Chem. 12 2004 5745
34. C. Singh, H. Malik, and S.K. Puri Bioorg. Med. Chem. Lett. 14 2004 459
35. C. Singh, H. Malik, and S.K. Puri Bioorg. Med. Chem. Lett. 15 2005 4484
36. C. Singh, H. Malik, and S.K. Puri J. Med. Chem. 49 2006 2794
37. C. Singh, R. Kanchan, D. Srivastava, and S.K. Puri Bioorg. Med. Chem. Lett. 16 2006 584
38. C. Singh, R. Kanchan, U. Sharma, and S.K. Puri J. Med. Chem. 50 2007 521
39. C. Singh, V.P. Verma, N.K. Naikade, A.S. Singh, M. Hassam, and S.K. Puri J. Med. Chem. 51 2008 7581
40. 3) δ 1.75-2.02 (m, 7H), 2.54-2.63 (m, 1H), 3.93 (d, 2H, J = 6.4 Hz), 5.35-5.38 (m, 2H), 5.53 (s, 1H), 7.08 (d, 2H, Ar, J = 8.7 Hz), 7.15 (d, 2H, Ar, J = 8.6 Hz), 7.35-7.51 (m, 5H, Ar), 7.63 (dd, 4H, Ar, J = 8.6 and 2.2 Hz);
41. (a) Peters, W. Techniques for the study of drug response in experimental malaria. In Chemotherapy and drug resistance in malaria; Academic Press: London, 1970; pp. 64-136.
42. 11 Mice treated with β-arteether served as positive control. Multidrug-resistant Plasmodium yoelii nigeriensis used in this study is resistant to chloroquine, mefloquine and halofantrine.
43. (a) One hundred percent protection means none of the treated mice developed patent infection during the 28 days observation period and hence recorded as cured. Similarly, 20% protection means only one out of five mice was cured.
44. (b) One hundred percent suppression of parasitaemia means no parasites were detected in 50 oil immersion microscopic fields (parasites if at all present, are below the detection limit). The parasites present below the detection limit can multiply and eventually can be detected during observation on subsequent days. In such cases though the drug is providing near 100% suppression of the parasitaemia on day 4 but will not provide full protection to the treated mice in the 28 day survival assay.
45. S.K. Puri, and N. Singh Expl. Parasitol. 94 2000 8